Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 19

CN18 - Challenges in genetic counseling in hereditary cancer syndromes in Mexican population and prevention clinic experience

Date

10 Sep 2022

Session

Poster session 19

Topics

Primary Prevention;  Genetic and Genomic Testing;  Cancer Epidemiology

Tumour Site

Presenters

Carlos Burciaga-Flores

Citation

Annals of Oncology (2022) 33 (suppl_7): S812-S814. 10.1016/annonc/annonc1042

Authors

C.H. Burciaga-Flores, M.L. Garza-Rodriguez, M.F. NORIEGA IRIONDO, O.A. Zayas, F. Alcorta-Nuñez, J.F. Gonzalez Guerrero, A. Alcorta-Garza, D. Hernandez Barajas, O. Vidal-Gutiérrez, D.C. Pérez-Ibave

Author affiliations

  • Medical Oncology Department, Hospital Universitario Dr José Eleuterio Gonzalez, 64460 - Monterrey/MX

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract CN18

Background

In Mexico genetic counseling is given by medical geneticists, the access is scarce added to socioeconomic characteristics of the population, reaching a definitive diagnosis in hereditary cancer syndromes is difficult. Therefore is underdiagnosed. The CUCC (Centro Universitario Contra el Cáncer) Early Cancer Detection Clinic (CECIL) create a model in which open population could enroll in a prevention cancer screening program.

Methods

From 2016-2021 a total of 3014 patients were enrolled. Patients were first filtered with a risk questionnaire prior consultation, those with at least one positive answer were selected to a genetic evaluation, and a second filter was made by the general physician. Also all patients referred from oncology consultation were evaluated. Those who fulfill hereditary cancer criteria were offered a genetic testing. Resources for the testing were obtained by patient pay, foundations, donations and research protocols.

Results

A total of 1119 subjects were evaluated. Of these 248 (21%) were candidates to genetic testing, only 149 (60%) could be analyzed, 52 probands (59%) and 32 relatives (51%) had at least one variant. Among the probands: 33 had HBOC (Hereditary Breast and Ovarian Cancer syndrome), 7 had Lynch, 1 LFS (Li-Fraumeni syndrome), 1 LFLS (Li-Fraumeni like syndrome), 1 FAP (Familial Adenomatous Polyposis), and 9 had benign variants. In the relatives group: 17 had Lynch, 10 HBOC, 1 LFS, and 4 FAP. To date 3 patients under surveillance had an in situ lesion, (1 endometrial and 2 colon), and 3 more had a premalignant colon lesion, one in the not tested group. To achieve low cost testing, 50%probands had partial sponsored, 31% patient paid, 13% by research and 4.5% by donations. Among relatives 94.4% were patient paid, and 5.5% by research, all relative were in-house low cost test.

Conclusions

The success of the model made awareness of these diseases, leading last year to the formation of a state detection program; including all public and private health institution with an oncology service refer their patients to this center. Also to found rising and agreements with laboratories to offer low cost genetic testing.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Unviersidad Autonoma de Nuevo León.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.